What is BriaCell Therapeutics Corp. (BCTX)?

BriaCell Therapeutics Corp. (BCTX) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of BCTX?

The current price of BCTX is $3.56. Prices are updated in real time on Stocks360.

What is BCTX's price-to-earnings (PE) ratio?

BCTX's trailing twelve-month PE ratio is -0.29, based on current price and earnings per share data available on Stocks360.

What is BCTX's market capitalization?

BCTX's market capitalization is $30,971,252.00, placing it in the small-cap tier.

BriaCell Therapeutics Corp. (BCTX)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$3.56

Market Cap

$30.97M

PE (TTM)

-0.29

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.52

Day Range

$3.45 – $3.62

52-wk Range

$2.60 – $13.80

Avg Volume

N/A

Volume

49.77K

BriaCell Therapeutics Corp. (BCTX) is a publicly traded company in the Healthcare sector. Latest price: $3.56. Market cap $30.97M. Trailing PE -0.29. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-28 · $13.34 2026-10-27 · $3.56 (-73.31%)

Earnings

Most Recent

Mar 10, 2026

EPS $-2.58 vs est. $-4.84

Beat by $2.26

Proprietary Signals

Signal snapshot temporarily unavailable.

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.29×
P/S (TTM)	0.00×
P/B	1.07×
P/FCF (TTM)	-1.00×
EV / EBITDA	-0.77×
EV / Sales	0.00×
Earnings Yield	-118.66%
Free Cash Flow Yield	-99.85%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$24.12M
Net Income (TTM)	-$36.78M
Free Cash Flow (TTM)	-$30.79M
Net Debt	-$6.88M
Working Capital	$21.80M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-147.92%
Return on Invested Capital	-136.31%